A breakthrough treatment may revolutionize high cholesterol management, as discovered by medical researchers in London.
Initial trials revealed that a single administration of the experimental VERVE-102 treatment reduced LDL “bad” cholesterol levels by up to 62% and maintained them at a low level for up to a year. This development offers hope that patients may no longer need daily medication for life.
Delivered intravenously, VERVE-102 works by permanently modifying genes involved in regulating cholesterol levels, as reported in the New England Medical Journal.
Lowering LDL cholesterol significantly decreases the accumulation of arterial plaque, reducing the risk of heart attack and stroke.
While statins can also reduce cholesterol, they typically require daily intake. If VERVE-102 proves safe and effective in larger studies, a single treatment could offer long-term cardiovascular protection.
Professor Riyaz Patel, a prominent figure in the trial, expressed excitement over the potential of this technology in cholesterol management.
“The promising results demonstrate the efficacy and safety of this treatment in lowering cholesterol levels,” Professor Patel noted.
Read more:
why is it important
Elevated LDL cholesterol poses a significant risk for cardiovascular events, resulting in numerous fatalities in the UK and US annually.
Despite the widespread use of statins, adherence remains a challenge, with about half of patients discontinuing treatment within a year due to various reasons, including side effects.
This underscores the importance of treatments like VERVE-102, offering a potential alternative to lifelong medication.
Treatment mechanism
A recent study involving adults with high cholesterol conditions demonstrated the efficacy of VERVE-102 in reducing LDL cholesterol levels through gene alteration.
The treatment, administered as a single infusion, targets liver cells to enhance LDL removal, mimicking a natural genetic mutation that leads to low cholesterol levels and reduced heart disease risk.
Further research is needed to validate the long-term safety and efficacy of this innovative approach.
How safe is it?
Contrary to misconceptions, VERVE-102 gene therapy makes targeted edits to liver cell genes without altering overall DNA, ensuring limited and localized genetic modifications.
This treatment does not affect hereditary genes passed onto offspring, emphasizing its safety profile, though continued monitoring is essential.
Leading experts, like Professor Brian Williams, commend the potential long-term benefits of reducing cardiovascular risks through such innovative therapies.
Further studies are required to assess the durability and safety of this groundbreaking gene therapy in a larger patient cohort.
However, caution is advised by experts like Professor Kaushik Ray, who stresses the need for long-term safety assessments before widespread adoption of gene therapies.
Ray highlights the importance of monitoring potential side effects and the necessity of supplementary medications for some patients with high cholesterol.
What else can gene editing treat?
This trial marks a milestone in gene editing, as it showcases the potential of somatic gene alterations to address prevalent health conditions like high cholesterol.
Professor Ewan Barney of the European Bioinformatics Laboratory recognizes the significance of this research in advancing somatic gene editing technologies for common diseases.
This breakthrough opens avenues for treating chronic conditions more effectively, offering hope for enhanced healthcare outcomes.
Read more:
Source: www.sciencefocus.com
